Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)

US9605066B2 · kind B2 · utility

Assignee

• Biotest AG · DE

Inventors

• Frank Osterroth · Dietzenbach, DE
• Christoph Uherek · Seligenstadt, DE
• Christoph Bruecher · Eschborn, DE
• Peter Röttgen · Ladenburg, DE
• Benjamin Daelken · Frankfurt am Main, DE
• André Engling · Frankfurt, DE
• Chantal Zuber · Frankfurt am Main, DE
• Niklas Czeloth · Dreieich, DE
• Andrea Wartenberg-Demand · Linden, DE
• Marcus Gutscher · Langen, DE
• Judith Wessels-Kranz · Frankfurt am Main, DE

Key dates

• Filing date: Aug 29, 2014
• Grant date: Mar 28, 2017
• Expiry date: Aug 29, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.